clinical trial · NCT05379634
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
Janssen Research & Development, LLC·phase2·active not recruiting·n = 36
MyositisNipocalimabPlaceboGlucocorticoids
brief summary
The purpose of this study is to evaluate the efficacy and safety of Nipocalimab versus placebo in participants with active idiopathic inflammatory myopathies (IIM).
started
Jul 5, 2022
primary completion
Sep 4, 2025
completion
Sep 16, 2026
last updated
Apr 13, 2026
official title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol